Dermata Therapeutics Warrant
DRMAW
6 hedge funds and large institutions have $278K invested in Dermata Therapeutics Warrant in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
45% less capital invested
Capital invested by funds: $506K → $278K (-$228K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$62K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$38.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $140K | – | – | – |
|
|
EAM
2
Empery Asset Management
New York
| $75K | +$138K | +175,000 | New |
|
|
WAM
3
Warberg Asset Management
Winnetka,
Illinois
| $22K | -$38.2K | -48,601 | -49% |
|
|
BFM
4
Boothbay Fund Management
New York
| $21K | – | – | – |
|
|
WVP
5
Worth Venture Partners
Fort Lee,
New Jersey
| $17K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $3K | +$3.12K | +3,960 | +132% |
|
|
7
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$62K | -75,000 | Closed |
|
DRMAW Hedge Fund Activity: Q4 2021 in Review
6 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q4 2021, worth a combined $278K — down 45% from $506K a quarter earlier.
Fund positioning in DRMAW was balanced in Q4 2021: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $3.12K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $62K sold.
- 6 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $278K of Dermata Therapeutics Warrant stock for Q4 2021, down 45% quarter-over-quarter.
- 1 fund opened new Dermata Therapeutics Warrant positions in Q4 2021 and 1 closed out, a net change of 0 holders.
- The largest Dermata Therapeutics Warrant buyer in Q4 2021 was UBS Group, an estimated $3.12K added.
- The largest Dermata Therapeutics Warrant seller in Q4 2021 was Hudson Bay Capital Management, an estimated $62K sold.
Based on aggregated 13F filings for Q4 2021.